U.S. FDA clears Israeli startup Sight Diagnostics' finger prick blood test -- MEDICA - World Forum for Medicine

04.12.2019

S.D Sight Diagnostics Ltd.

U.S. FDA clears Israeli startup Sight Diagnostics' finger prick blood test

The regulator’s nod means that laboratories that run relatively lesser tests on a day to day basis may also be able to conduct the complete blood count (CBC) test with just two drops of blood.

“This could be a big change because at the moment a traditional analyzer can be placed in laboratories that run thousands of tests every week,” said Sarah Levy, chief technical officer at Sight Diagnostics.

CBC is a blood test that gives a snapshot of one’s overall health and can also used to detect leukemia. The FDA clearance could bring down costs at laboratories with lower volumes, as traditional CBC tests which use a technology known as flow cytometry, normally require dedicated personnel to maintain the device, adding to costs.

Exhibitor Data Sheet